Accessibility Menu
Vicore Pharma Ab (publ) logo

Vicore Pharma Ab (publ)(NASDAQ) VCRE

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-30%
5 YearN/A
1 YearN/A
1 MonthN/A
$11.32
-0.53%
-0.06Today
Vicore Pharma Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 11.062026-07-27
Vicore Pharma Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.32%USD 11.442026-07-20
Since inception-29.97%USD 16.252026-07-06

Vicore Pharma Ab (publ) Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.32

Volume

22

Open

$11.32

Previous Close

$11.32

Daily Range

$11.32 - $11.32

52-Week Range

$11.00 - $17.80

Estimated Earnings Date

Aug 21, 2026

VCRE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vicore Pharma Ab (publ)

Vicore Pharma Holding AB is a pharmaceutical company focused on developing innovative drugs for interstitial lung diseases and related indications. Founded in 2000 and headquartered in Stockholm, Sweden, the company is dedicated to addressing unmet medical needs in the healthcare sector.

Products and Services
  • VP01: A drug targeting interstitial lung diseases
  • VP02: Focused on related respiratory conditions
  • VP03 and VP04: Additional drug development programs in the pipeline
Growth Outlook
  • Strong focus on niche markets with high unmet medical needs
  • Potential for significant market expansion in respiratory therapies
  • Ongoing clinical trials may lead to new product approvals
Financial Highlights
  • Recent stock price range between 13.55 and 16.53
  • Quarterly trading volume of 25,928 shares
  • Market capitalization remains stable, indicating investor interest
Vicore Pharma Holding AB is positioned in a specialized segment of the pharmaceutical industry, focusing on interstitial lung diseases. The company's drug development programs, including VP01, VP02, VP03, and VP04, aim to address significant medical needs. The growth outlook is promising, with a strong emphasis on niche markets and ongoing clinical trials that could lead to new product approvals. Recent financial highlights indicate a stable stock price range and consistent trading volume, reflecting investor interest in the company's potential.
AI Generated • Jul 7, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Stockholm, AB 171 65, SE

VCRE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

22

Avg. Volume

55.79K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Vicore Pharma Ab (publ) Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About VCRE

What is the current price of Vicore Pharma Ab (publ)?

Vicore Pharma Ab (publ) is trading at $11.32 per share.

What is the 52-week range for Vicore Pharma Ab (publ)?

Over the past 52 weeks, Vicore Pharma Ab (publ) has traded between $11.00 and $17.80.

How much debt does Vicore Pharma Ab (publ) have?

Vicore Pharma Ab (publ) total debt is unavailable.

How much cash does Vicore Pharma Ab (publ) have on hand?

Vicore Pharma Ab (publ) does not have cash on hand data available.

What is Vicore Pharma Ab (publ)’s dividend yield?

Vicore Pharma Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services